| Methods |
2‐week placebo run‐in period; inclusion criteria= supine DBP >/= 95 mm Hg after run‐in; 12‐week double‐blind treatment, forced titration (dose doubled) every 4 weeks starting at 10 mg |
| Participants |
Enalapril 10 mg: n=31(17 males,14 females); mean age=56 years; baseline SBP=152.5(13.4) mm Hg, DBP=102.5(5.0) mm Hg;
Placebo: n=29(17 males,12 females); mean age=53 years; baseline SBP=149.8(14.5) mm Hg, DBP=100.2(4.3) mm Hg |
| Interventions |
Enalapril 10 mg once daily;
Placebo;
average dosing time 9 AM |
| Outcomes |
Mean change from baseline in trough sitting SBP/DBP using mercury sphygmomanometer;
WDAE |
| Notes |
Used week 4 BP data only; BP change and SE of change reported, endpoint BP and endpoint SE reported, calculated SD of change from N and SE of change; SBP data from Table 2, p. 496; DBP data from Table 3, p. 497; Jadad score=3; funding source= Lederle Laboratories |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
